Smac mimetics induce inflammation and necrotic tumour cell death by modulating macrophage activity

Cell Death and Disease

Volumn 4, Issue 11, 2013, Pages

  Lecis, D ^a   De Cesare, M ^a   Perego, P ^a   Conti, A ^a   Corna, E ^a   Drago, C ^b   Seneci, P ^c,d   Walczak, H ^e   Colombo, M P ^a   Delia, D ^a   Sangaletti, S ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d CISI   (Italy)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

IAPs; Inflammation; Innate immunity; Ovarian cancer ascites; Smac mimetics

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; PEPTIDOMIMETIC AGENT; SMAC MIMETIC 83; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; CANCER SURVIVAL; CARCINOMA CELL; CELL ACTIVITY; CELL DEATH; DRUG ACTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MONOTHERAPY; MOUSE; NEUTROPHIL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SARCOMA CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMIMETIC MATERIALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELLS, CULTURED; FEMALE; HCT116 CELLS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INHIBITOR OF APOPTOSIS PROTEINS; MACROPHAGES; MICE; MICE, INBRED BALB C; NECROSIS; NEUTROPHILS; OVARIAN NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84889564559     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.449     Document Type: Article

References (56)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674
2. Gyrd-Hansen M, Meier P. IAPs: From caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010; 10: 561-574
3. Lopez J, John SW, Tenev T, Rautureau GJ, Hinds MG, Francalanci F, et al. CARDmediated autoinhibition of cIAP1's E3 ligase activity suppresses cell proliferation and migration. Mol Cell 2011; 42: 569-583
4. Fingas CD, Blechacz BR, Smoot RL, Guicciardi ME, Mott J, Bronk SF, et al. A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology 2010; 52: 550-561
5. Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, Salvesen GS, et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem 1998; 273: 7787-7790
6. Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, et al. A conserved XIAPinteraction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 2001; 410: 112-116
7. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388: 300-304
8. Oost TK, Sun C, Armstrong RC, Al-Assaad A, Betz SF, Deckwerth TL, et al. Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 2004; 47: 4417-4426
9. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule smac mimic potentiates TRAIL-And TNF{alpha}-mediated cell death. Science 2004; 305: 1471-1474
10. Seneci P, Bianchi A, Battaglia C, Belvisi L, Bolognesi M, Caprini A, et al. Rational design, synthesis and characterization of potent, non-peptidic Smac mimics/XIAP inhibitors as proapoptotic agents for cancer therapy. Bioorg Med Chem 2009; 17: 5834-5856
11. Probst BL, Liu L, Ramesh V, Li L, Sun H, Minna JD, et al. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-Alpha-dependent manner. Cell Death Differ 2010; 17: 1645-1654
12. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009; 69: 2425-2434
13. Lecis D, Drago C, Manzoni L, Seneci P, Scolastico C, Mastrangelo E, et al. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib. Br J Cancer 2010; 102: 1707-1716
14. Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S, et al. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol Cancer Ther 2011; 10: 902-914
15. Feltham R, Bettjeman B, Budhidarmo R, Mace PD, Shirley S, Condon SM, et al. SMAC-mimetics activate the E3 ligase activity of cIAP1 by promoting RING dimerisation. J Biol Chem 2011; 286: 17015-17028
16. Darding M, Feltham R, Tenev T, Bianchi K, Benetatos C, Silke J, et al. Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. Cell Death Differ 2011; 18: 1376-1386
17. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFa-dependent apoptosis. Cell 2007; 131: 682-693
18. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kB activation, and TNFadependent apoptosis. Cell 2007; 131: 669-681
19. Moulin M, Anderton H, Voss AK, Thomas T, Wong WW, Bankovacki A, et al. IAPs limit activation of RIP kinases by TNF receptor 1 during development. EMBO J 2012; 31: 1679-1691
20. Eschenburg G, Eggert A, Schramm A, Lode HN, Hundsdoerfer P. Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF-Alpha independent apoptosis. Cancer Res 2012; 72: 2645-2656
21. Greer RM, Peyton M, Larsen JE, Girard L, Xie Y, Gazdar AF, et al. SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAPdependent but TNF-Alpha-independent manner. Cancer Res 2011; 71: 7640-7648
22. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010; 177: 1053-1064
23. Sica A, Mantovani A. Macrophage plasticity and polarization: In vivo veritas. J Clin Invest 2012; 122: 787-795
24. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-Associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anticancer therapy. Eur J Cancer 2006; 42: 717-727
25. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: An immunologic functional perspective. Annu Rev Immunol 2009; 27: 451-483
26. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005; 65: 3437-3446
27. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, et al.' 'Re-educating'' tumor-Associated macrophages by targeting NF-kB. J Exp Med 2008; 205: 1261-1268
28. Manzoni L, Belvisi L, Bianchi A, Conti A, Drago C, de Matteo M, et al. Homo-And heterodimeric Smac mimetics/IAP inhibitors as in vivo-Active pro-Apoptotic agents. Part I: Synthesis. Bioorg Med Chem 2012; 20: 6687-6708
29. Lecis D, Mastrangelo E, Belvisi L, Bolognesi M, Civera M, Cossu F, et al. Dimeric Smac mimetics/IAP inhibitors as in vivo-Active pro-Apoptotic agents. Part II: Structural and biological characterization. Bioorg Med Chem 2012; 20: 6709-6723
30. Gaither A, Porter D, Yao Y, Borawski J, Yang G, Donovan J, et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-{alpha} signaling. Cancer Res 2007; 67: 11493-11498
31. Muller-Sienerth N, Dietz L, Holtz P, Kapp M, Grigoleit GU, Schmuck C, et al. SMAC mimetic BV6 induces cell death in monocytes and maturation of monocyte-derived dendritic cells. PLoS One 2011; 6: E21556
32. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, Gros P, et al. Endotoxintolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 1999; 189: 615-625
33. Sitia G, Iannacone M, Muller S, Bianchi ME, Guidotti LG. Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol 2007; 81: 100-107
34. Colombo MP, Modesti A, Parmiani G, Forni G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-Talk. Cancer Res 1992; 52: 4853-4857
35. Granot Z, Henke E, Comen EA, King TA, Norton L, Benezra R. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 2011; 20: 300-314
36. Stoppacciaro A, Melani C, Parenza M, Mastracchio A, Bassi C, Baroni C, et al. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma. J Exp Med 1993; 178: 151-161
37. Bonta IL, Ben-Efraim S. Involvement of inflammatory mediators in macrophage antitumor activity. J Leukoc Biol 1993; 54: 613-626
38. Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH, Gorter A, Welters MJ, et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4 Th1 cells. J Immunol 2011; 187: 1157-1165
39. Said NA, Elmarakby AA, Imig JD, Fulton DJ, Motamed K. SPARC ameliorates ovarian cancer-Associated inflammation. Neoplasia 2008; 10: 1092-1104
40. Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011; 17: 6083-6096
41. Jeon BH, Jang C, Han J, Kataru RP, Piao L, Jung K, et al. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b macrophages in advanced ovarian cancer. Cancer Res 2008; 68: 1100-1109
42. Emeagi PU, Van Lint S, Goyvaerts C, Maenhout S, Cauwels A, McNeish IA, et al. Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy. Cancer Res 2012; 72: 1342-1352
43. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of highmobility group box-1 protein. Immunity 2008; 29: 21-32
44. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010; 28: 367-388
45. Bartholomae WC, Rininsland FH, Eisenberg JC, Boehm BO, Lehmann PV, Tary-Lehmann M. T cell immunity induced by live, necrotic, and apoptotic tumor cells. J Immunol 2004; 173: 1012-1022
46. Dineen SP, Roland CL, Greer R, Carbon JG, Toombs JE, Gupta P, et al. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res 2010; 70: 2852-2861
47. Cossu F, Milani M, Vachette P, Malvezzi F, Grassi S, Lecis D, et al. Structural insight into inhibitor of apoptosis proteins recognition by a potent divalent smac-mimetic. PLoS One 2012; 7: E49527
48. Sun H, Nikolovska-Coleska Z, Lu J, Meagher JL, Yang CY, Qiu S, et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc 2007; 129: 15279-15294
49. Sangaletti S, Tripodo C, Ratti C, Piconese S, Porcasi R, Salcedo R, et al. Oncogene-driven intrinsic inflammation induces leukocyte production of tumor necrosis factor that critically contributes to mammary carcinogenesis. Cancer Res 2010; 70: 7764-7775
50. Calcaterra C, Sfondrini L, Rossini A, Sommariva M, Rumio C, Menard S, et al. Critical role of TLR9 in acute graft-versus-host disease. J Immunol 2008; 181: 6132-6139
51. De Cesare M, Sfondrini L, Campiglio M, Sommariva M, Bianchi F, Perego P, et al. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN. J Immunother 2010; 33: 8-15
52. Watanabe N, Niitsu Y, Sone H, Neda H, Urushizaki I, Yamamoto A, et al. Therapeutic effect of endogenous tumor necrosis factor on ascites Meth A sarcoma. J Immunopharmacol 1986; 8: 271-283
53. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-426
54. Sangaletti S, Tripodo C, Chiodoni C, Guarnotta C, Cappetti B, Casalini P, et al. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood 2012; 120: 3007-3018
55. Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M, et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 2007; 14: 431-441
56. Clark RA, Nauseef WM. Isolation and Functional Analysis of Neutrophils. Current Protocols in Immunology. John Wiley & Sons, Inc, 2001